Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2000
10/19/2000WO2000061754A2 Human proteins and polynucleotides encoding them
10/19/2000WO2000061748A1 48 human secreted proteins
10/19/2000WO2000061737A2 Production of attenuated negative stranded rna virus vaccines
10/19/2000WO2000061736A2 Recombinant and mutant marek's disease virus
10/19/2000WO2000061724A2 Anti-bacterial vaccine compositions
10/19/2000WO2000061628A1 49 human secreted proteins
10/19/2000WO2000061625A1 48 human secreted proteins
10/19/2000WO2000061620A1 49 human secreted proteins
10/19/2000WO2000061616A1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
10/19/2000WO2000061611A2 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
10/19/2000WO2000061604A2 Pharmaceutical compounds
10/19/2000WO2000061596A1 50 human secreted proteins
10/19/2000WO2000061595A1 The novel antisense-oligos with better stability and antisense effect
10/19/2000WO2000061593A1 Erythromycin derivatives
10/19/2000WO2000061583A1 Xanthine derivatives and analogs as cell signaling inhibitors
10/19/2000WO2000061564A1 Antiviral pyrimidinedione derivatives and process for the preparation thereof
10/19/2000WO2000061563A1 Antiviral pyrimidinedione derivatives and process for the preparation thereof
10/19/2000WO2000061555A1 Indigoid bisindole derivatives
10/19/2000WO2000061551A2 Pyrimidine-2-one derivatives as integrin receptor ligands
10/19/2000WO2000061545A1 Methods for solid phase combinatorial synthesis of integrin inhibitors
10/19/2000WO2000061542A1 Caspase inhibitors and the use thereof
10/19/2000WO2000061541A2 Pharmaceutical compounds
10/19/2000WO2000061221A1 Method of providing cosmetic/medical therapy
10/19/2000WO2000061190A2 Treatment of intracellular infection
10/19/2000WO2000061189A2 Water-soluble compositions of bioactive lipophilic compounds
10/19/2000WO2000061184A2 Dry formulation for transcutaneous immunization
10/19/2000WO2000061171A2 Uses of mammalian ox2 protein and related reagents
10/19/2000WO2000061161A2 A pharmaceutical formulation useful for the treatment of hepatitis b, hepatitis c and other viral infections of the liver and a process for its preparation
10/19/2000WO2000061160A2 A pharmaceutical formulation useful for the treatment of hepatitis b hepatitis c and other viral infections of the liver and a pr ocess for its preparation
10/19/2000WO2000061153A1 Medicinal compositions and their method of preparation
10/19/2000WO2000061149A1 Long-acting antibacterial composition
10/19/2000WO2000061134A1 Antimicrobial agents
10/19/2000WO2000061118A1 Anhydrous tablet of ranitidine hydrochloride with double-layer coating and its composition
10/19/2000WO2000061116A2 Pharmaceutical formulation comprising amoxycillin and clavulanate
10/19/2000WO2000061115A2 Pharmaceutical formulation comprising amoxycillin
10/19/2000WO2000061067A2 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
10/19/2000WO2000042992A3 Compositions and methods for mucosal delivery
10/19/2000WO2000041505A3 Anthranilic acid derivatives
10/19/2000WO2000038711A3 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
10/19/2000WO2000037103A3 Compounds for intracellular delivery of therapeutic moieties to nerve cells
10/19/2000WO2000034308A3 Protein transduction system and methods of use thereof
10/19/2000WO2000033872A3 Method of and compositions for immunization with the pseudomonas v antigen
10/19/2000WO2000029551A3 Cells, culture methods, and their use in autologous transplantation therapy
10/19/2000WO2000024437A3 Textured and porous silicone rubber
10/19/2000WO2000012720A8 Elongase genes and uses thereof
10/19/2000WO2000012507A8 Pyrrolobenzodiazepines
10/19/2000DE19916837A1 New di- or tetrahydro-benzoazulene derivatives, are integrin inhibitors useful e.g. for treating thrombosis, coronary heart disease, arteriosclerosis, tumors, osteoporosis or rheumatoid arthritis
10/19/2000CA2815763A1 Anti-bacterial vaccine compositions
10/19/2000CA2760534A1 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
10/19/2000CA2696826A1 Process for preparing inhibitors of nucleoside metabolism
10/19/2000CA2372078A1 Treatment of intracellular infection
10/19/2000CA2371172A1 50 human secreted proteins
10/19/2000CA2370767A1 49 human secreted proteins
10/19/2000CA2370563A1 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
10/19/2000CA2370523A1 49 human secreted proteins
10/19/2000CA2370425A1 Pharmaceutical compounds
10/19/2000CA2370189A1 48 human secreted proteins
10/19/2000CA2369981A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
10/19/2000CA2369976A1 The novel antisense-oligos with better stability and antisense effect
10/19/2000CA2369817A1 Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
10/19/2000CA2369684A1 Novel method of treatment
10/19/2000CA2369670A1 Indigoid bisindole derivatives
10/19/2000CA2369619A1 Caspase inhibitors and the use thereof
10/19/2000CA2369454A1 Uses of mammalian ox2 protein and related reagents
10/19/2000CA2369272A1 Medicinal compositions and their method of preparation
10/19/2000CA2369200A1 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
10/19/2000CA2368655A1 Dry formulation for transcutaneous immunization
10/19/2000CA2368049A1 Integrin receptor ligands
10/19/2000CA2367319A1 Erythromycin derivatives
10/19/2000CA2366520A1 Anti-bacterial vaccine compositions
10/19/2000CA2366359A1 Novel essential bacterial genes and their proteins
10/19/2000CA2365929A1 Novel method for identifying antibacterial compounds
10/19/2000CA2365918A1 49 human secreted proteins
10/19/2000CA2365917A1 Bone morphogenic proteins
10/19/2000CA2365915A1 Recombinant toxin a/toxin b vaccine against clostridium difficile
10/19/2000CA2365914A1 Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
10/19/2000CA2365913A1 Tumor necrosis factor receptor homologs and nucleic acids encoding the same
10/19/2000CA2365910A1 Human proteins and polynucleotides encoding them
10/19/2000CA2365905A1 48 human secreted proteins
10/19/2000CA2365901A1 Tissue-specific and pathogen-specific toxic agents and ribozymes
10/19/2000CA2364690A1 Novel transduction molecules and methods for using same
10/19/2000CA2364536A1 Fragments of virus protein 2 or 3 of polyoma virus, as vehicules for active substances
10/19/2000CA2356128A1 Method of providing cosmetic/medical therapy
10/19/2000CA2334754A1 A pharmaceutical formulation useful for the treatment of hepatitis b, hepatitis c and other viral infections of the liver and a process for its preparation
10/19/2000CA2306039A1 Hcv combination therapy
10/18/2000EP1044987A2 Gapped 2'-modified oligonucleotides
10/18/2000EP1044983A1 Antibiotic tkr2999, process for the preparation thereof and microbe
10/18/2000EP1044977A1 Camptothecin derivatives having antitumor activity
10/18/2000EP1044972A1 5,6,7-TRINOR-4,8-INTER-m-PHENYLENE PGI2 DERIVATIVE AND DRUGS CONTAINING THE SAME
10/18/2000EP1044685A2 Farnesol derivatives for morphological transition control over dimorphic fungi
10/18/2000EP1044680A1 Novel method of treatment using a high dosage regimen of amoxycillin and potassium clavulanate
10/18/2000EP1044273A2 COMPOSITIONS DERIVED FROM $i(MYCOBACTERIUM VACCAE) AND METHODS FOR THEIR USE
10/18/2000EP1044266A2 Human signal peptide-containing proteins
10/18/2000EP1044211A1 36 human secreted proteins
10/18/2000EP1044208A1 Erythromycin derivatives
10/18/2000EP1044207A1 Novel macrolides
10/18/2000EP1044201A1 3-substituted adenines via2-thioxanthines
10/18/2000EP1044020A2 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
10/18/2000EP1044019A1 Methods and compositions for desensitisation
10/18/2000EP1044006A1 Use of an antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
1 ... 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 ... 1798